MENUNews Archive
Date: 06/03/2022
Scientists at the University of Michigan Rogel Cancer Center were optimistic when they identified a small molecule that blocked a key pathway in brain tumors. But there was a problem: How to get the inhibitor through the bloodstream and into the brain to reach the tumor. In collaboration with multiple labs, the teams fabricated a nanoparticle to contain the inhibitor, and the results were even better than expected.
Date: 05/26/2022
More than 30 Rogel Cancer Center-led research efforts will be presented during the 2022 ASCO Annual Meeting, running June 3-7 at McCormick Place in Chicago, Illinois, and online.
Date: 05/26/2022
Men with advanced prostate cancer taking abiraterone or enzalutamide plus hormone therapy were at higher risk of serious medical issues than their peers undergoing hormone therapy alone.
Date: 05/20/2022
The Rogel Cancer Center has recently appointed four faculty members to named professorships. A named professorship is the highest honor a department or center can bestow upon a faculty member. Professorships are made possible by the generosity of donors.
Date: 05/16/2022
In early research led by the University of Michigan Health Rogel Cancer Center, the oral medication zanubrutinib was found to help most patients with a slow-growing type of cancer known as marginal zone lymphoma. Cancers shrunk in 80% of the 20 patients on the clinical trial with marginal zone lymphoma, with a fifth experiencing complete remission.
Date: 05/02/2022
In mice, nanomedicine can remodel the immune microenvironment in lymph node and tumor tissue for long-term remission and lung tumor elimination in this form of metastasized breast cancer.
Date: 04/28/2022
The University of Michigan Rogel Cancer Center will provide funding support to 12 exceptional faculty researchers, 2 early career clinical researchers and six medical and graduate students. In addition, the center has launched a new program for Rogel Scholars in Cancer Health Equity, to support two faculty members who are working to address the cancer burden in historically underserved or excluded populations.
Date: 04/25/2022
By using an artificial intelligence-based system, researchers improved doctors' assessment of whether patients with bladder cancer had a complete response to chemotherapy before undergoing a radical cystectomy (bladder cancer removal surgery).
Date: 04/20/2022
Noninvasive sound technology developed at the University of Michigan breaks down liver tumors in rats, kills cancer cells and spurs the immune system to prevent further spread—an advance that could lead to improved cancer outcomes in humans.
Date: 04/20/2022
The Emerging Leaders Council (ELC) is comprised of 15 early career faculty members interested in taking a larger role in the cancer center. Candidates are selected by the SLC and serve 3-year terms. The council is led by a chair, and two co-chairs elected by the ELC members to serve one-year terms.